Drug delivery devices with drug-permeable component and methods

Patent metadata

Field	Value
Publication number	US-11285304-B2
Application number	US-201916405139-A
Country	US
Kind code	B2
Filing date	May 7, 2019
Priority date	Mar 15, 2013
Publication date	Mar 29, 2022
Grant date	Mar 29, 2022

Abstract

Implantable drug delivery devices include a housing having a closed drug reservoir lumen bounded by a first wall structure and a hydrophilic second wall structure, and a drug contained in the drug reservoir lumen, wherein the first wall structure is impermeable to the drug and the second wall structure is permeable to the drug. Methods of providing controlled release of drug to a patient include deploying a drug delivery device in the patient releasing a drug from the drug reservoir lumen via diffusion through the second wall structure.

First claim

We claim:

1. A drug delivery device comprising:
a housing having a closed drug reservoir lumen bounded by a first wall structure constructed of a first material and a hydrophilic second wall structure constructed of a second material different from the first material; and
a drug contained in the drug reservoir lumen,
wherein the first wall structure is impermeable to the drug, and the second material of the second wall structure is permeable to the drug by diffusion,
wherein the first wall structure and the second wall structure are adjacent to one another and together form an elongated tube, and
wherein the second wall structure is a longitudinal strip extending along at least a portion of an entire length of the tube.

2. The device of claim 1 , wherein the device is configured for deployment and retention in a body cavity or lumen.

3. The device of claim 2 , wherein the body cavity is other than the bladder.

4. The device of claim 2 , wherein the device is elastically deformable between a relatively straightened shape and a retention shape suited to retain the device within the body cavity.

5. The device of claim 2 , further comprising a retention frame lumen and a retention frame disposed therein.

6. The device of claim 1 , wherein the first material comprises silicone.

7. The device of claim 6 , wherein the silicone has a Shore hardness of from 50A to 70A.

8. The device of claim 1 , wherein the second material comprises a thermoplastic polyurethane.

9. The device of claim 8 , wherein the thermoplastic polyurethane has a Shore hardness of from 80A to 65D.

10. The device of claim 1 , wherein the first material comprises silicone and the second material comprises a thermoplastic polyurethane.

11. The device of claim 1 , wherein the first wall structure and the second wall structure are formed in a coextrusion process.

12. The device of claim 1 , wherein the drug is in the form of one or more solid drug units.

13. The device of claim 1 , wherein the drug is a low solubility drug.

14. The device of claim 1 , wherein the drug is a high solubility drug.

15. The device of claim 1 , wherein the device is configured to release solubilized drug from the closed drug reservoir lumen by the diffusion through the second material, upon the drug being contacted by water that enters the drug reservoir lumen through the first wall structure or through the first and second wall structures.

16. The device of claim 1 , wherein the longitudinal strip extends along the entire length of the tube.

17. A drug delivery device comprising:
a housing having a drug reservoir lumen bounded by a first wall structure constructed of a first material and a second wall structure constructed of a second material different from the first material, wherein the first wall structure and the second wall structure are adjacent to one another and together form an elongated tube in which the second wall structure is a longitudinal strip extending along an entire length of the tube; and
a plurality of tablets which comprise a drug, wherein the plurality of tablets are contained in the drug reservoir lumen,
wherein the first wall structure is impermeable to the drug, and the second material of the second wall structure is permeable to the drug, and
wherein the second material comprises a hydrophilic thermoplastic polyurethane and has a Shore hardness of 70A or greater.

18. The device of claim 17 , wherein the second material has a Shore hardness between 70A and 65D.

19. The device of claim 17 , wherein the device is configured to release solubilized drug from the drug reservoir lumen by diffusion through the second material, following contact of the drug tablets with water that enters the drug reservoir lumen through the first and second wall structures.

20. The device of claim 17 , wherein the device is elastically deformable between a relatively straightened shape and a coiled retention shape.

21. The device of claim 20 , further comprising a retention frame lumen and a retention frame disposed therein.

22. The device of claim 21 , wherein the retention frame comprises a nitinol wire.

23. The device of claim 17 , wherein the drug is a kinase inhibitor.

24. The device of claim 17 , wherein the drug is gemcitabine.

Assignees

• Taris Biomedical Llc

Inventors

• Lee Heejin
• Daniel Karen
• Sansone Matthew

Classifications

• A61M2205/04

  implanted · CPC title

• A61M2205/02

  characterised by a particular materials · CPC title

• A61M31/007

  Injectors for solid bodies, e.g. suppositories · CPC title

• A61M31/002 Primary

  Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50) · CPC title

• A61K33/243

  Platinum; Compounds thereof · CPC title